AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21885257 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (previously developed to accurately identify Meyer's loop for planning anterior temporal lobe resection)
Number of subjects: 10
Study 21885257 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (more automated technique to reduce operator time and depict the entire optic radiation)
Number of subjects: 10
Study 18162423 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (B1) followed by Glutamate (B2)
Number of subjects: 15
Study 18162423 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate (D1) followed by Capsaicin (D2)
Number of subjects: 15
Study 18162423 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate or Capsaicin injection
Number of subjects: 15
Study 18162423 — intervention group
Group type: COMPARATOR
Intervention: Isotonic Saline (A1) followed by Glutamate (A2)
Number of subjects: 15
Study 18162423 — intervention group
Group type: COMPARATOR
Intervention: Isotonic Saline (C1) followed by Capsaicin (C2)
Number of subjects: 15
Study 16579666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional weight-bearing exercise program
Number of subjects: 91
Study 12665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular HES (6% HES 130/0.4) (n=20)
Number of subjects: 40
Study 12665995 — intervention group
Group type: COMPARATOR
Intervention: Gelatin (n=20)
Number of subjects: 40
Study 12665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 10555884 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (40 mg oral AL/day)
Number of subjects: 32
Study 10555884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9038444 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 60
Study 9038444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube
Number of subjects: 60
Study 9038444 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 60
Study 1974748 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐adrenoceptor blocking agents (treated group, n = 39)
Number of subjects: 61
Study 1974748 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (0.5%‐0.6% end‐tidal) plus 50% nitrous oxide
Number of subjects: 61
Study 1974748 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 22, no preoperative beta-blocker therapy)
Number of subjects: 61
Study 6454387 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 21
Study 6454387 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 21
Study 31785551 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported poorly controlled hypertension
Number of subjects: 0
Study 30829120 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self‐testing (HIVST)
Number of subjects: 40
Study 30829120 — intervention group
Group type: COMPARATOR
Intervention: HIV counselling and testing (HCT)
Number of subjects: 40
Study 27876460 — intervention group
Group type: EXPERIMENTAL
Intervention: IMO-8400
Number of subjects: 46
Study 27876460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 25594360 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenovela intervention (culturally congruent videotaped dramatization with guided dialogue)
Number of subjects: 0
Study 25594360 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25594360 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenovela intervention
Number of subjects: 0
Study 25058107 — intervention group
Group type: EXPERIMENTAL
Intervention: Land Exercise (LE)
Number of subjects: 58
Study 25058107 — intervention group
Group type: COMPARATOR
Intervention: Aquatic Exercise (AE)
Number of subjects: 58
Study 22789796 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated support programme
Number of subjects: 12
Study 22789796 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care with integrated support programme
Number of subjects: 12
Study 22789796 — intervention group
Group type: COMPARATOR
Intervention: Medical care without integrated support programme (Control)
Number of subjects: 12
Study 19937785 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-maintaining technique (WMT)
Number of subjects: 103
Study 19937785 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 103
Study 19937785 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WMT and CT
Number of subjects: 103
Study 17356969 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted program of education and reminders delivered to primary care physicians, mailings and automated telephone calls to patients.
Number of subjects: 241
Study 17356969 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 241
Study 15998890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg every other day)
Number of subjects: 39876
Study 11860644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray administration
Number of subjects: 10
Study 11860644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal drop administration
Number of subjects: 10
Study 10442381 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (150 mg/m2/day) plus oral calcium folinate (90 mg/day) plus radiotherapy (45 Gy total)
Number of subjects: 11
Study 7844596 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (AlloBMT)
Number of subjects: 287
Study 7844596 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CHEMO)
Number of subjects: 287
Study 2895592 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 100
Study 2895592 — intervention group
Group type: COMPARATOR
Intervention: Temazepam 20 mg
Number of subjects: 100
Study 2895592 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg and Temazepam 20 mg
Number of subjects: 100
Study 30973315 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate goal‐contingent rewards
Number of subjects: 96
Study 30973315 — intervention group
Group type: COMPARATOR
Intervention: Delayed rewards
Number of subjects: 96
Study 30973315 — intervention group
Group type: COMPARATOR
Intervention: Immediate goal‐contingent rewards and Delayed rewards
Number of subjects: 96
Study 30691766 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 12
Study 30691766 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 30691766 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 12
Study 28408697 — intervention group
Group type: EXPERIMENTAL
Intervention: CaHMB with BC30
Number of subjects: 26
Study 28408697 — intervention group
Group type: EXPERIMENTAL
Intervention: CaHMB with placebo
Number of subjects: 26
Study 28408697 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 26
Study 26147835 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum (AS) eye drops
Number of subjects: 37
Study 26147835 — intervention group
Group type: COMPARATOR
Intervention: Bandage contact lens (BCL)
Number of subjects: 37
Study 23886213 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX regimen (gemcitabine at 1000 mg/m² by fixed-dose rate infusion at 10 mg/m²/min on days 1 and 8, and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Number of subjects: 64
Study 23886213 — intervention group
Group type: COMPARATOR
Intervention: Control group (gemcitabine at 1000 mg/m² by intravenous infusion within 30 min on days 1 and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Number of subjects: 64
Study 23886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 21680632 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymised information sharing
Number of subjects: 0
Study 18422779 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MCP (rituximab, mitoxantrone, chlorambucil, and prednisolone)
Number of subjects: 43
Study 18422779 — intervention group
Group type: COMPARATOR
Intervention: MCP (mitoxantrone, chlorambucil, and prednisolone)
Number of subjects: 43
Study 20541220 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine augmentation (olanzapine + divalproex)
Number of subjects: 101
Study 16195134 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg/day)
Number of subjects: 115
Study 16195134 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg/day)
Number of subjects: 115
Study 11900100 — intervention group
Group type: EXPERIMENTAL
Intervention: Humans
Number of subjects: 0
Study 11900100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigeons
Number of subjects: 0
Study 9713084 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral balloon valvuloplasty
Number of subjects: 88
Study 9713084 — intervention group
Group type: COMPARATOR
Intervention: Open commissurotomy
Number of subjects: 88
Study 8040443 — intervention group
Group type: EXPERIMENTAL
Intervention: CT during arterial portography (CTAP)
Number of subjects: 40
Study 8040443 — intervention group
Group type: EXPERIMENTAL
Intervention: Short tau inversion recovery MRI (STIR)
Number of subjects: 40
Study 8040443 — intervention group
Group type: COMPARATOR
Intervention: CTAP
Number of subjects: 40
Study 8040443 — intervention group
Group type: COMPARATOR
Intervention: STIR MRI
Number of subjects: 40
Study 8040443 — intervention group
Group type: EXPERIMENTAL
Intervention: CTAP and STIR MRI
Number of subjects: 40
Study 3394908 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam in propylene glycol
Number of subjects: 12
Study 3394908 — intervention group
Group type: COMPARATOR
Intervention: Diazepam in lipid formulation
Number of subjects: 12
Study 3394908 — intervention group
Group type: COMPARATOR
Intervention: Diazepam in mixed micelles
Number of subjects: 12
Study 11694683 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 746
Study 11694683 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 746
Study 30740748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum daily dose of 900 mg)
Number of subjects: 234
Study 30740748 — intervention group
Group type: COMPARATOR
Intervention: Baclofen (maximum daily dose of 60 mg)
Number of subjects: 234
Study 30740748 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 234
Study 30740748 — intervention group
Group type: COMPARATOR
Intervention: Baclofen
Number of subjects: 234
Study 29964036 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance-guided therapy for 14 days (n=21 in trial 1, n=205 in trial 2)
Number of subjects: 441
Study 29964036 — intervention group
Group type: COMPARATOR
Intervention: Empirical therapy for 14 days (n=20 in trial 1, n=205 in trial 2)
Number of subjects: 441
Study 29964036 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline sequential therapy (part of trial 1)
Number of subjects: 441
Study 26908153 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits from a Visual Rehabilitation Officer
Number of subjects: 30
Study 26908153 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30
Study 24443851 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 24443851 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 60
Study 22915637 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS 100 mg/day
Number of subjects: 253
Study 22915637 — intervention group
Group type: COMPARATOR
Intervention: IM 400 mg/day
Number of subjects: 253
Study 19906525 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS plus reflexology
Number of subjects: 183
Study 19906525 — intervention group
Group type: COMPARATOR
Intervention: SIS plus scalp massage (control)
Number of subjects: 183
Study 16842931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 0
Study 16842931 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 0
Study 14999212 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 59
Study 14999212 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 59
Study 11581440 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH once a day (qd)
Number of subjects: 282
Study 11581440 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (IR MPH) 3 times a day (tid)
Number of subjects: 282
Study 11581440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 11581440 — intervention group
Group type: EXPERIMENTAL
Intervention: IR MPH tid
Number of subjects: 282
Study 11581440 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS MPH qd
Number of subjects: 282
Study 9842765 — intervention group
Group type: COMPARATOR
Intervention: Normal speed condition
Number of subjects: 0
Study 9842765 — intervention group
Group type: COMPARATOR
Intervention: Fast speed condition
Number of subjects: 0
Study 9842765 — intervention group
Group type: EXPERIMENTAL
Intervention: Huntington's disease subjects
Number of subjects: 0
Study 7986459 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 19
Study 7986459 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 19
Study 2646838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (80 mg/day)
Number of subjects: 396
Study 2646838 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted contour detection system (CAAS)
Number of subjects: 396
Study 2646838 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with 10 mg isosorbide dinitrate sublingually
Number of subjects: 396
Study 29370485 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudsley Staging Method (MSM)
Number of subjects: 643
Study 28281196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation via I‐neb®
Number of subjects: 0
Study 28281196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation via Turbuhaler®
Number of subjects: 0
Study 28281196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation via new dry powder inhaler (new DPI)
Number of subjects: 0
Study 28281196 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation via Spira®
Number of subjects: 0
Study 28281196 — intervention group
Group type: COMPARATOR
Intervention: Predicted lung deposited dose
Number of subjects: 0
Study 26651465 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based recovery training (6 sessions)
Number of subjects: 128
Study 26651465 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based recovery training
Number of subjects: 128
Study 26651465 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 128
Study 24565484 — intervention group
Group type: EXPERIMENTAL
Intervention: Auvi-Q
Number of subjects: 693
Study 24565484 — intervention group
Group type: COMPARATOR
Intervention: EpiPen
Number of subjects: 693
Study 22030760 — intervention group
Group type: EXPERIMENTAL
Intervention: non-RS protocol
Number of subjects: 41
Study 22030760 — intervention group
Group type: COMPARATOR
Intervention: RS protocol
Number of subjects: 41
Study 18444532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril (25 mg)
Number of subjects: 50
Study 18444532 — intervention group
Group type: COMPARATOR
Intervention: Oral nicardipine (20 mg)
Number of subjects: 50
Study 17160221 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team approach in a Diabetes Center (DC)
Number of subjects: 205
Study 17160221 — intervention group
Group type: COMPARATOR
Intervention: Endocrinologist-only approach
Number of subjects: 205
Study 14979419 — intervention group
Group type: EXPERIMENTAL
Intervention: Controllable perfusion-related variables during CPB (e.g., hematocrit, mean arterial pressure, thermic perfusion, blood lactate, colloid osmotic pressure, pulsatile perfusion, acid base homeostasis, oxygenation, coated circuitry)
Number of subjects: 0
Study 14979419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality Assessment Perfusion Score (MAPS)
Number of subjects: 0
Study 10548210 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with a bolus of 1.5 mg piritramide and a 10-min lockout interval
Number of subjects: 120
Study 10548210 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA combined with nonsteroidal anti-inflammatory drugs prescribed three times per day
Number of subjects: 120
Study 10548210 — intervention group
Group type: COMPARATOR
Intervention: Conventional nurse-controlled analgesia
Number of subjects: 120
Study 10999062 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 30
Study 10999062 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 30
Study 1899325 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (250 mg three or four times a day)
Number of subjects: 12
Study 1899325 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 1899325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6350401 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (n = 50)
Number of subjects: 92
Study 6350401 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 92
Study 31638455 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A
Number of subjects: 0
Study 31638455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30314833 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Radial (DR) approach
Number of subjects: 200
Study 30314833 — intervention group
Group type: COMPARATOR
Intervention: Traditional Radial (TR) approach
Number of subjects: 200
Study 28740972 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE spacer
Number of subjects: 50
Study 28740972 — intervention group
Group type: COMPARATOR
Intervention: Cotton spacer
Number of subjects: 50
Study 26906629 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial open-group behavioural weight-loss programme
Number of subjects: 23
Study 25161043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaco-invasive (PI) strategy
Number of subjects: 1884
Study 25161043 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1884
Study 22149452 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (100 mmol daily)
Number of subjects: 21
Study 22149452 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study 18022292 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1382
Study 18022292 — intervention group
Group type: EXPERIMENTAL
Intervention: High midlife total cholesterol (TC)
Number of subjects: 1382
Study 18022292 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in TC over time
Number of subjects: 1382
Study 18022292 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1382
Study 17079070 — intervention group
Group type: EXPERIMENTAL
Intervention: VLRP with rhabdosphincter reconstruction (VLRP-R)
Number of subjects: 62
Study 17079070 — intervention group
Group type: COMPARATOR
Intervention: Standard VLRP
Number of subjects: 62
Study 15859523 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11886688 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75-225 mg/day
Number of subjects: 301
Study 11886688 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20-60 mg/day
Number of subjects: 301
Study 11886688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 10074873 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 359
Study 10074873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 359
Study 10074873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 359
Study 7673949 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (0.1 mg/kg/day orally for 12 months)
Number of subjects: 44
Study 7673949 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil + Plasma Exchange (15 courses during the first 4 months)
Number of subjects: 44
Study 7673949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 2169778 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40-200 micrograms/kg, 30 min infusion)
Number of subjects: 0
Study 2169778 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (160 micrograms/kg, 3 min infusion)
Number of subjects: 0
Study 2169778 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (up to 160 micrograms/kg b.d. for 7 days)
Number of subjects: 0
Study 2169778 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 0
Study 2169778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6785059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir
Number of subjects: 38
Study 6785059 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (TFT)
Number of subjects: 38
Study 6785059 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Aciclovir and TFT)
Number of subjects: 38
Study 31179485 — intervention group
Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis
Number of subjects: 495
Study 31179485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 28197938 — intervention group
Group type: EXPERIMENTAL
Intervention: Taohong Siwu Decoction (TSD) plus oral prednisone
Number of subjects: 148
Study 28197938 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral prednisone
Number of subjects: 148
Study 29231407 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-snake moxibustion
Number of subjects: 120
Study 29231407 — intervention group
Group type: COMPARATOR
Intervention: Warm needling
Number of subjects: 120
Study 29231407 — intervention group
Group type: COMPARATOR
Intervention: Western medication (methotrexate)
Number of subjects: 120
Study 24439349 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive e‐referral to Decide2Quit.org
Number of subjects: 1814
Study 24439349 — intervention group
Group type: COMPARATOR
Intervention: Paper referrals to Decide2Quit.org
Number of subjects: 1814